Cases with cytogenetic abnormalities - details of staging, treatment and follow-up.
| Case No. | Age/sex | Cytogenetic |
Modified Rai staging | Binet staging | Treatment | Time to treatment | Follow-up period |
|---|---|---|---|---|---|---|---|
| 4 | 57/M | Del (13q) | High | C | 6 cycles of BR, achieved CR, followed by 5 cycles of Len maintenance | 5 mo | 18 mo |
| 5 | 63/M | Trisomy 12 | Intermediate | B | 6 cycles of BR, attained PR, now on observation | 1 mo | 18 mo |
| 6 | 51/F | Del (13q) | Intermediate | A | - | - | Lost to follow-up |
| 8 | 63/F | Del (11q) | High | C | Observation | - | 2 mo |
| 11 | 57/M | Del (11q) | High | C | - | - | Lost to follow-up |
| 15 | 80/M | Del (13q) | Low | A | Observation | - | 18 mo |
| 19 | 55/F | Del (13q) | Low | A | Observation | - | 6 mo |
| 21 | 48/M | Del (13q)+Trisomy 12 | High | C | Observation | - | 18 mo |
| 22 | 60/F | Del (13q) | Low | A | - | - | Lost to follow-up |
| 23 | 70/M | Del (17p) | Intermediate | B | 2 cycles of BR, then 6 cycles of R-Len, achieved PR, now Len maintenance | 0.2 mo | 16 mo |
| 24 | 74/M | Del (13q) | Intermediate | A | Observation | - | 16 mo |
| 34 | 57/M | Trisomy 12 | Intermediate | A | Observation | - | 14 mo |
| 35 | 50/F | Del (13q) | Low | A | - | - | Lost to follow-up |
| 36 | 67/M | Del (11q) | High | C | 3 cycles of R-Clb | 2 mo | 4 mo |
| 39 | 69/M | Trisomy 12+NOTCH1 mutation | Intermediate | B | 6 cycles of R-Clb, achieved PR, now 4 cycles of Len maintenance | 2 mo | 13 mo |
| 40 | 62/M | Del (13q) | Intermediate | B | 4 cycles of BR | 7.5 mo | 13 mo |
| 42 | 73/M | Del (13q) | High | C | - | - | Lost to follow-up |
| 44 | 80/M | Del (11q) | Low | A | - | - | Lost to follow-up |
| 45 | 66/M | Del (11q) | High | C | - | - | Lost to follow-up |
| 50 | 70/M | Del (13q) | Intermediate | A | Observation | - | 12 mos |
| 51 | 63/M | Trisomy 12 | Low | A | Observation | - | 12 mo |
| 52 | 62/F | Del (13q) | Intermediate | A | Observation | - | 5 mo |
| 53 | 65/M | Del (13q) | High | B | 6 cycles of BR, achieved PR | 3.5 mo | 12 mo |
| 56 | 65/F | Del (13q) | High | C | 9 cycles of R-Clb | 1.5 mo | 11 mo |
| 57 | 65/M | Del (13q) | Intermediate | A | Observation | - | 11 mo |
| 61 | 68/F | Del (13q) | Low | A | Observation | - | 10 mo |
| 65 | 66/F | Trisomy 12 | High | C | 5 cycles of Clb-Pred completed | 2.5 mo | 9 mo |
| 68 | 80/F | Del (13q) | Low | A | Observation | - | 9 mo |
| 71 | 86/M | Del (13q) | Intermediate | A | - | - | Lost to follow-up |
| 72 | 67/M | Trisomy 12 | Intermediate | C | Observation | - | 8 mo |
| 74 | 50/F | Del (13q) | High | C | Observation | - | 8 mo |
| 76 | 74/F | Del (13q)+Del (17p) | Low | A | - | - | Lost to follow-up |
| 77 | 78/M | Del (13q) | High | C | - | - | Lost to follow-up |
| 78 | 75/M | Del (13q) | Intermediate | A | - | - | Lost to follow-up |
Abbreviations: BR, bendamustine plus rituximab; Clb-Pred, chlorambucil+prednisolone; CR, complete response; Len, lenalidomide; PR, partial response; R-Clb, rituximab+chlorambucil; R-Len, rituximab+lenalidomide.
Blood Res 2020;55:131~138 https://doi.org/10.5045/br.2020.2020080
© Blood Research
© 2024. BLOOD RESEARCH All rights reserved. Powered by INFOrang Co., Ltd